| Name | Title | Contact Details |
|---|
FMD K&L is a global contract research organization supporting data management, biostatistics, statistical programming, clinical operations, regulatory affairs, safety, pharmacovigilance, toxicology, medical affairs, medical writing, quality, risk, and compliance services to the pharmaceutical, biotechnology, and medical device industries worldwide. We continuously strive to raise the standard of excellence through accuracy and efficiency to achieve the highest quality output for our partners. K&L was established in the US in 1995, and has grown rapidly worldwide, with key offices and delivery centers in the US, UK, China, India, Armenia, Japan and throughout the Asia-Pacific region.
Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd`s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.
89 North is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics.
Cibus is part of the multi-billion-dollar plant seed industry. Cibus leads the new era of high throughput gene editing technology that can develop plant traits precisely at a fraction of the time and cost of conventional breeding. Cibus is not a seed company. We are a technology company that uses gene editing to develop plant traits. Cibus licenses its traits to seed companies for royalties on seeds that use its traits. Cibus` target market is Productivity Traits” that improve yields, lower input costs such as chemicals and increase the sustainability and profitability of farming. We has a pipeline of six productivity traits including traits for pod shatter reduction, disease resistance and nutrient use efficiency. Cibus` focus is multi-crop traits for the major crops: canola, rice, soybean, wheat, and corn. In other words, traits that can impact global agriculture sustainability at scale. Technology: Gene editing in agriculture is a plant breeding technology. The promise of gene editing in agriculture is the ability to develop plant traits that are indistinguishable from traits developed using conventional breeding but can be developed at a fraction of the time and cost. To many, gene editing represents agriculture`s “analog to digital” technology moment. It is a technology that changes the speed and scale of trait development. Cibus is at the forefront of this technology moment. Our Rapid Trait Development System™ (RTDS®) and Trait Machine™ process represents the first end-to-end semi-automated plant breeding system. Vision: Cibus` vision is to be a pure play trait developer; a technology company whose business is to develop and license plant traits to seed companies in exchange for royalties. The licensing of plant traits and germplasm with quantifiable benefits and strong intellectual property is an integral part of the seed industry. Our goal is to be a leader in this segment of the seed industry.